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By virtue of being the product of the genetic admixture of three ancestral roots: Europeans,
Africans, and Amerindians, the present-day Brazilian population displays very high levels
of genomic diversity, which have important pharmacogenetic/-genomic (PGx) implications.
Recognition of this fact has prompted the creation of the Brazilian Pharmacogenomics Net-
work (Refargen), a nationwide consortium of research groups, with the mission to provide
leadership in PGx research and education in Brazil, with a population heath impact. Here,
we present original data and review published results from a Refargen comprehensive
study of the distribution of PGx polymorphisms in a representative cohort of the Brazilian
people, comprising 1,034 healthy, unrelated adults, self-identified as white, brown, or black,
according to the Color categories adopted by the Brazilian Census. Multinomial log-linear
regression analysis was applied to infer the statistical association between allele, geno-
type, and haplotype distributions among Brazilians (response variables) and self-reported
Color, geographical region, and biogeographical ancestry (explanatory variables), whereas
Wright’s F ST statistics was used to assess the extent of PGx divergence among differ-
ent strata of the Brazilian population. Major PGx implications of these findings are: first,
extrapolation of data from relatively well-defined ethnic groups is clearly not applicable to
the majority of Brazilians; second, the frequency distribution of polymorphisms in several
pharmacogenes of clinical relevance (e.g., ABCB1, CYP3A5, CYP2C9, VKORC ) varies con-
tinuously among Brazilians and is not captured by race/Color self-identification; third, the
intrinsic heterogeneity of the Brazilian population must be acknowledged in the design and
interpretation of PGx studies in order to avoid spurious conclusions based on improper
matching of study cohorts.
Keywords: biogeographical ancestry, Brazilian pharmacogenomic network, F ST statistics, pharmacogenomic
diversity, population admixture, refargen
INTRODUCTION
The present-day Brazilian population, in excess of 190 million
people, is highly heterogeneous and admixed, as result of five cen-
turies of mating between native Amerindians, Europeans, and sub-
Saharan Africans. This fact renders inappropriate extrapolation of
pharmacogenetic/-genomic (PGx) data derived from well-defined
ethnic groups to the majority of Brazilians. Recognition of this fact
has prompted the creation of the Brazilian Pharmacogenomics
Network or Refargen (Suarez-Kurtz, 2004), a nationwide consor-
tium of research groups, mostly from academia1. In consonance
with its mission to provide leadership in PGx research and edu-
cation in Brazil, with impact on population heath (Suarez-Kurtz,
2009), Refargen has recently concluded a comprehensive study
of the distribution of PGx polymorphisms among Brazilians. In
this article, we will present original data and review previously
published results (Suarez-Kurtz et al., 2010, 2012a,b,c; Pena et al.,
2011; Sortica et al., 2012) from the Refargen study and discuss the
1http://www.refargen.org.br
PGx implications of the findings for Brazilians and possibly other
admixed populations of the Americas.
The study cohort consisted of 1,034 healthy, unrelated adults
recruited in the North, Northeast, Southeast, and South regions
of Brazil (Figure 1). Each individual signed a written informed
consent and was asked to self-identify according to the classifi-
cation scheme adopted by the Brazilian Census2, which relies on
self-perception of skin color. Accordingly, the subjects were dis-
tributed into three groups: branco (White, n= 342), pardo (Brown,
n= 350), and preto (Black, n= 342). The term Color is capitalized
throughout the text, to call attention to its special meaning in
the context of the Brazilian Census classification. This cohort is
considered representative of the present-day Brazilian population
since 99% of Brazilians self-identify in one of the three Color
categories, and 93% live in one of the four regions, included in
the study3. Individuals from the Center-West region (7% of the
2http://www.ibge.gov.br
3http://www.sidra.ibge.gov.br/bda/tabela/listabl.asp?z=t&c=262
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FIGURE 1 | Map of Brazil, showing its five geographical regions, their
populations (in millions), and cities where individuals were recruited
for the Refargen study, reviewed in this article.
Brazilian population) and those classified as “Yellow” (meaning
Asian descendants,0.7%) or Amerindian (0.3%) were not included
in the study. We genotyped 44 loci in 12 pharmacogenes (Table 1)
which modulate drug metabolism (CYP2B6, CYP2C8, CYP2C9,
CYP2C19, CYP2D6, CYP3A5, COMT, and TPMT ), transport
(ABCB1, SLCO1B1, and SLCO1B3) and effect (VKORC1). Phar-
macogenomics Knowledge Base (PharmGKB4) lists all these genes,
except SCLO1B3, as “Important PGx genes (VIP)” and two thirds
of the 44 polymorphisms investigated as “Important Variants.”
We will initially present data for the overall cohort and for each
Color group within this cohort. Figure 2 shows frequency his-
tograms of the total number of minor alleles identified in each
individual. No statistically significant difference (Kruskal–Wallis
test p= 0.92) was detected across the three Color groups, the
median (interquartile range) number of polymorphisms being
17 (14–20), 16 (13–18), and 16 (13–19) in White, Brown, and
Black individuals. This adds to 18.9% of the total number of
alleles genotyped at the 44 loci in the overall cohort. However,
the allele frequency at 11 of these loci differed significantly (chi
square p< 0.05) across the Color groups. The pharmacogenes
affected were ABCB1 (2 SNPs),CYP2C8 (1) CYP3A5 (3),NAT2 (3),
SLCO1B1 (1), SCLO1B3 (2 SNPs, which are in complete LD) and
VKORC1 (2). We applied the Wright’s F ST statistics (Wright, 1951)
to estimate the extent of PGx divergence among the three Color
strata, and observed mean F ST values of 0.005 (SD 0.006), 0.013
(0.017), and 0.004 (0.005) for pair-wise comparisons of White vs.
Brown, White vs. Black, and Brown vs. Black, respectively (Suarez-
Kurtz et al., 2012b). According to Wright’s qualitative guidelines
(Wright, 1978), F ST values lower than 0.05 denote low genetic
4http://www.pharmgkb.org/search/browseVip.action?browseKey=annotatedGenes
diversity, whereas values between 0.05 and 0.15 indicate mod-
erate diversity. As shown in Table 1, only three SNPs, namely
CYP3A5∗3 and the linked SLCO1B3 334T>C and 699G>A tran-
sitions exceeded, and two other SNPs (ABCB1 2677G> nonG and
CYP3A5∗6) approached, the F ST threshold for moderate genetic
divergence in White vs. Black Brazilians in the entire cohort.
Not surprisingly, these were the SNPs with the smallest p val-
ues for the Kruskal–Wallis analyses of frequency distribution in
the overall cohort (<0.0001–0.0006, Table 1). Taken together, the
F ST analyses in the overall cohort suggest low PGx divergence at
all loci interrogated in self-identified Brown vs. White or Black
individuals, whereas moderate divergence was observed at three,
and possibly five loci (out of the 44 investigated) in pair-wise
comparisons of White vs. Black Brazilians.
DISTRIBUTION OF PHARMACOGENETIC POLYMORPHISMS
AMONG BRAZILIANS ACCORDING TO COLOR CATEGORIES
AND GEOGRAPHICAL REGIONS
With an area of 8,511,960 Km2, Brazil is a country of conti-
nental size (the fifth largest in the world) and different regions
have diverse population histories. For instance, the North had
a large influence of the Amerindian root, the Northeast had
a history of strong African presence due to slavery and the
South was mostly settled by European immigrants (Pena et al.,
2011). We have applied multinomial log-linear regression analy-
ses (Suarez-Kurtz et al., 2010, 2012c; Sortica et al., 2012) to
infer the statistical association between allele, genotype, and hap-
lotype distributions among Brazilians (response variables) and
self-reported Color and geographical region (explanatory vari-
ables). This procedure obviates the need for correction for multiple
comparisons, because the main effects and interaction terms are
tested simultaneously within each regression context. Table 2
illustrates results from this exercise, applied to selected genes
affecting drug metabolism (CYP2C8, CYP2C9, and CYP2C19),
transport (ABCB1 and SLCO1B1) and response (VKORC1). Color
per se associates significantly with the frequency distribution
of CYP2C8 and CYP2C9 variant alleles, ABCB1 and SLCO1B1
haplotypes, and VKOC1 3673G >A alleles and genotypes; no
association is observed with respect to the CYP2C19 polymor-
phisms. Color in combination with geographical region is sig-
nificantly associated with distribution of CYP2C8 and CYP2C9
alleles, ABCB1 and SLCO1B1 haplotypes, whereas geographi-
cal region per se associates with CYP2C8 and CYP2C9 allele
frequency.
We explored further the PGx heterogeneity among Brazil-
ians by the F ST statistics. First, we performed pair-wise com-
parisons between Color groups within each geographical region,
and detected significant differences in the distribution of F ST val-
ues for White vs. Brown (P < 0.0001, ANOVA) and White vs.
Black (P < 0.0001), but not Brown vs. Black individuals, across
regions (Suarez-Kurtz et al., 2012b). This implies that the extent
of pharmacogenetic divergence between Whites and Non-Whites
(i.e., Black and Brown individuals) varies significantly among
regions. The data presented in Figure 3 supports this interpreta-
tion: we show that 10 selected polymorphisms in ABCB1, CYP2D6,
CYP3A5, SLCO1B1, SCLO1B3, and VKORC1 display moderate
divergence between Whites and Blacks in the South, compared
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Table 1 | Distribution of pharmacogenetic polymorphisms among Brazilians.
Gene Polymorphism Id # Effect Minor allele frequency Chi square F ST






ABCB1 1267C>T rs1128503 G412G 0.380 0.412 0.362 0.312 0.18 0.011 0.003 0.003
2677G>T/A rs2032582 S193A/T 0.370 0.417 0.343 0.221 0.0006 0.044 0.006 0.019
3435C>T rs1045642 I1145I 0.427 0.458 0.411 0.317 0.037 0.021 0.002 0.009
COMT 472G>A rs4680 V158M 0.408 0.437 0.374 0.411 0.52 0.001 0.004 0.001
CYP2B6 64C>T rs8192709 R22C 0.081 0.067 0.099 0.078 0.60 0.001 0.003 0.001
785A>G rs2279343 K262R 0.303 0.295 0.300 0.374 0.22 0.007 0.000 0.006
1459C>T rs3211371 R487C 0.172 0.213 0.135 0.127 0.068 0.013 0.011 0.000
516G>T rs3745274 Q172H 0.369 0.393 0.325 0.458 0.055 0.004 0.005 0.019
CYP2C8 805A>T rs11572103 I269F 0.047 0.026 0.060 0.106 0.012 0.026 0.007 0.007
416G>A rs11572080 R139K 0.098 0.125 0.075 0.058 0.08 0.014 0.007 0.001
792C>G rs1058930 I264M 0.038 0.040 0.039 0.020 0.54 0.004 0.000 0.003
CYP2C9 430C>T rs1799853 R144C 0.108 0.137 0.082 0.066 0.08 0.004 0.001 0.007
1075A>C rs1057910 I359L 0.052 0.049 0.059 0.026 0.26 0.014 0.008 0.001
1080C>G rs28371686 D360E 0.005 0.004 0.005 0.009 1.0 0.001 0.000 0.000
1003C>T rs28371685 R335W 0.008 0.010 0.005 0.009 0.78 0.000 0.001 0.000
CYP2C19 681G>A rs4244285 Splicing defect 0.115 0.106 0.120 0.144 0.58 0.003 0.001 0.001
636G>A rs4986893 W212X 0.000 0.000 0.000 0.003 1.0 0.000 0.000 0.000
−806C>T rs12248560 Increased
transcription
0.169 0.168 0.167 0.175 0.98 0.000 0.000 0.000
CYP2D6 −1584C>G rs1080985 Promoter region 0.218 0.235 0.207 0.178 0.64 0.003 0.003 0.000
31G>A rs769258 V11M 0.035 0.043 0.027 0.023 0.60 0.002 0.002 0.000
100C>T rs1065852 P34S 0.136 0.150 0.124 0.115 0.79 0.003 0.002 0.000
1023C>T rs28371706 T107I 0.044 0.021 0.057 0.111 0.08 0.025 0.011 0.003
1661G>C rs1058164 V136V 0.456 0.461 0.445 0.482 0.89 0.000 0.000 0.001
1846G>A rs3892097 Splicing defect 0.117 0.134 0.105 0.080 0.61 0.003 0.004 0.000
2549A>del rs35742686 Frame shift 0.009 0.011 0.007 0.006 0.60 0.000 0.000 0.000
2615-2617delAAG rs5030656 K281del 0.013 0.014 0.011 0.013 1.0 0.001 0.002 0.001
2850C>T rs16947 R296C 0.390 0.352 0.417 0.480 0.23 0.016 0.003 0.005
3183G>A rs59421388 V287M 0.026 0.011 0.038 0.056 0.25 0.021 0.011 0.002
4180G>C rs1135840 S486T 0.531 0.513 0.541 0.582 0.74 0.004 0.000 0.002
CYP3A5 6986A>G rs776746 Frame shift 0.698 0.785 0.627 0.541 <0.0001 0.067 0.030 0.007
14690G>A rs10264272 Splicing defect 0.027 0.004 0.039 0.105 0.0001 0.049 0.014 0.017
23132insT rs413003343 Frame shift 0.024 0.013 0.027 0.079 0.003 0.025 0.003 0.013
SLCO1B1 388A>G rs2306283 N130D 0.553 0.498 0.601 0.635 0.036 0.019 0.011 0.001
463C>A rs11045819 P155T 0.118 0.118 0.122 0.097 0.77 0.001 0.000 0.002
521T>C rs4149056 V174A 0.135 0.135 0.143 0.089 0.24 0.005 0.000 0.007
SLCO1B3 334T>G rs4149117 S112A 0.741 0.799 0.702 0.592 0.0003 0.051 0.013 0.013
699G>A rs7311358 M233I 0.741 0.799 0.702 0.592 0.0003 0.051 0.013 0.013
TMPT 238G>C rs1800462 A80P 0.008 0.001 0.014 0.014 0.36 0.006 0.006 0.000
460G>A rs1800460 A154T 0.010 0.009 0.011 0.010 0.82 0.000 0.000 0.000
719A>G rs1142345 Y240C 0.026 0.017 0.037 0.017 0.46 0.000 0.004 0.004
VKORC1 3673G>A rs9923231 Reduced
transcription
0.333 0.371 0.306 0.238 0.038 0.021 0.005 0.006
5808C>T rs2884737 Intronic 0.193 0.255 0.135 0.128 0.003 0.026 0.023 0.000
6853G>C rs8050894 Intronic 0.392 0.404 0.386 0.357 0.65 0.002 0.000 0.001
9104G>A rs7294 3-UTP 0.375 0.376 0.372 0.379 0.65 0.000 0.000 0.000
Bold numbers in the column “chi square” indicate statistically significant P values; bold numbers in the “White vs. Black” column indicate moderate pharmacogenetic
divergence.
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FIGURE 2 | Frequency histograms of the distribution of 44 PGx
polymorphisms among self-identified (White n=342), Brown
(n= 352), and Black Brazilians (n=342). The data represent the total
number of minor alleles at the 44 loci, in each individual.
Table 2 | Multinominal log-linear analyses of the distribution of
pharmacogenetic polymorphisms alleles among Brazilians according
to self-reported color and geographical region.






CYP2C8 *2, *3, *4 <0.0001 0.71 0.04
CYP2C9 *2, *3, *5, *11 <0.0001 0.23 0.01
CYP2C19 *2, *3, *17 0.60 0.11 0.33
ABCB1 haplotypesb <0.001 0.001 0.013
SLCO1B1 haplotypesc <0.001 0.001 0.003
VKORC1 3673A allele 0.0004 0.07 0.11
3673A genotype 0.002 0.18 0.19
ap values associated to the “main effects” (Color and geographical region) and
their “interaction.”
bHaplotypes comprising the 1236C>T, 2677G>nonG, and 3435C>T loci.
cHaplotypes comprising the 388A>G, 463C>A, and 521T>C loci.
to five, one, and zero in the Southeast, North, and Northeast,
respectively. In a second exercise, we compared F ST values for
each Color between regions and present the results in Figure 4. Of
the 792 (44 polymorphisms× six pair-wise regions× three Color
groups) comparisons, only three SNPs among Black, one among
Brown, and one among White individuals exceeded the thresh-
old (F ST= 0.05) for moderate PGx divergence. Taken together,
FIGURE 3 | Allele-specific F ST values for 10 PGx polymorphisms (x -axis)
in White vs. Black Brazilians recruited at the North, Northeast,
Southeast, and South regions. The dashed line shows the threshold F ST
values (0.05) for moderate genetic divergence. The genes and loci for each
polymorphism are presented inTable 1.
FIGURE 4 | Allele-specific F ST values (y -axis) for pair-wise comparisons
between geographical regions (x -axis). Data are presented separately
for self-identified Black (top panel), Brown (middle panel), and White
(bottom panel) individuals. Each symbol correspond to one of the 44
polymorphisms listed inTable 1. The dashed line shows the threshold F ST
values (0.05) for moderate genetic divergence. NO, North; NE, Northeast;
SE, Southeast; SO, South.
these F ST results extend the conclusions of the multinomial analy-
ses described above, that the distribution of PGx polymorphisms
among Brazilians is influenced by self-reported Color, geograph-
ical region, and the interaction of these two variables. Collec-
tively, these data reflect the notorious heterogeneity of the Brazil-
ian population and highlight the inappropriateness of ascribing
PGx polymorphisms’ frequencies for “Brazilians” based on data
from one or more Color strata recruited at a given region (or
city).
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IMPACT OF BIOGEOGRAPHICAL ANCESTRY ON THE
DISTRIBUTION OF PHARMACOGENETIC POLYMORPHISMS
AMONG BRAZILIANS
These analyses were based on the individual proportions of Euro-
pean, African, and Amerindian ancestry, estimated using a panel
of short insertion/deletion polymorphisms, validated as ancestry-
informative markers (Bastos-Rodrigues et al., 2006), and the
STRUCTURE clustering software (Pritchard et al., 2000). These
data, available for 965 subjects confirmed that the vast major-
ity of Brazilians, irrespective of self-reported Color, share Euro-
pean and African ancestries in variable proportions, and a sizable
number of individuals display also distinct Amerindian ancestry
(Suarez-Kurtz and Pena, 2006, 2007; Suarez-Kurtz et al., 2010;
Pena et al., 2011). The average proportions of European ances-
try decrease progressively from self-reported White (mean 0.80,
SD 0.21, n= 325), to Brown (0.62, 0.29, 322) and then to Black
individuals (0.46, 0.20, 318), and the opposite trend is observed
with respect to African ancestry, which averaged 0.10 (SD 0.14) in
White, 0.25 (0.26) in Brown, and 0.42 (0.29) in Black persons.
However, the individual proportions of European and African
ancestry varies widely, and most importantly, as a continuum
within each of these three Color categories, whereas the individual
proportion of Amerindian ancestry remains relatively constant
across the three groups, ranging from 0.10 to 0.13. To describe
the association between PGx polymorphisms and the estimated
individual biogeographical ancestry we fitted non-linear logis-
tic regression modeling using maximum likelihood estimation.
A consistent finding in these analyses (Suarez-Kurtz et al., 2007a,b,
2010, 2012c; Estrela et al., 2008; Vargens et al., 2008) is that the
frequency distribution of PGx polymorphisms among Brazilians
is best fit by continuous functions of the individual proportions of
African and European ancestry. This is illustrated in Figures 5 and
6. In Figure 5 we show that the probability of having the wild-type
(C/G/C) and the T/G/C ABCB1 haplotypes increases continuously
with the increase in African ancestry, whereas the opposite trend
is observed for the T/nonG/T haplotype. Figure 6 shows that
the odds of having the heterozygous, and to a lesser extent, the
homozygous variant genotype at the VKORC1 3673G>A locus
increase progressively as the individual proportion of European
ancestry increases. For comparison, we also display in Figure 6 the
distribution of VKORC1 3673G>A genotypes among Portuguese,
by far the most important source of European migrants from
Brazil, and individuals from Angola and Mozambique, two for-
mer Portuguese colonies in Africa, and origin of enslaved Africans
brought to Brazil.
Considering that the European and African components
together account for 89% of the diversity in individual genetic
ancestry in the Refargen cohort (Pena et al., 2011), it might
be anticipated that: (a) the greater the difference in frequency
of a given polymorphism between Europeans and sub-Saharan
Africans, the wider the range of frequency variation among Brazil-
ians; (b) the range of variation among Brazilians will be smaller
than the difference in frequency between Europeans and Africans,
because of the admixture of these ancestral roots in Brazilians. We
have previously verified both these predictions for polymorphisms
in VKORC1 (Suarez-Kurtz et al., 2010) and within the CYP2C
cluster (Suarez-Kurtz et al., 2012c). We applied the F ST statistics
FIGURE 5 | Effect display for the distribution ofABCB1 haplotypes in
the logit model fit to the data for African ancestry in 965 Brazilians. The
haplotypes comprising the 1236C>T, 2677G>nonG, and 3435C>T SNPs
are shown at the right of the plot. The individual proportion of African
ancestry is shown in the x -axis. The y -axis is labeled on the probability
scale. The plot was generated as described by Venables and Ripley (2002)
and implemented as function “multinom” available in the R package
“nnet.” Data from Sortica et al. (2012).
to examine these predictions in 38 polymorphisms which were
genotyped in the Refargen cohort and also in the HapMap project.
In Figure 7 we shown the pair-wise F ST values for each polymor-
phism in HapMap CEU vs. YRI cohorts – taken as proxies of the
European and sub-Saharan African ancestral roots of Brazilians,
respectively – and Brazilians with >90% European ancestry vs.
Brazilians with >80% African ancestry. The attenuation of phar-
macogenetic divergence between the Brazilian groups compared
to the HapMap populations is evident.
CONCLUDING REMARKS AND PERSPECTIVES
The kaleidoscopic diversity of the admixed Brazilian population,
with tri-hybrid biogeographical ancestry in Europe, Africa, and
America adds complexity to, but also creates advantages for PGx
research. Advantages include the opportunity to explore PGx
associations in individuals with heterogeneous genetic ancestry
under similar environmental and socio-economical conditions,
and to gather information on peoples that are excluded or under-
represented in clinical drug trials, such as sub-Saharan Africans
and Native Americans. A major challenge to PGx studies in Brazil is
population stratification,which if not controlled for,will confound
the outcomes of PGx association studies. Our studies describe
ways to control for this caveat, by combining ancestry-informative
markers and appropriate statistical approaches. A distinct message
that emerges from these studies is that race/color categorization
does not capture the distribution of PGx polymorphisms among
Brazilians, which is best modeled by continuous functions of the
individual proportions of European and African ancestry, irrespec-
tive of self-identified Color (Suarez-Kurtz, 2010). Recognition of
this fact is important in the design and interpretation of PGx clini-
cal trials in Brazilians but does not imply that PGx-informed drug
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FIGURE 6 | Effect display for the distribution ofVKORC1 3673G>A
genotypes in the logit model fit to the data for African ancestry in
965 Brazilians (B). For comparison the frequency of each genotype in
a cohort of Angolans and Mozambicans [n=216, (A)] and in a
Portuguese cohort [n=89, (C)] are also shown. The individual
proportion of African ancestry in Brazilians is shown in the x -axis. The
y -axis represents the genotype probability for Brazilians and the
observed genotype frequency for the African and Portuguese cohorts.
Data from Suarez-Kurtz et al. (2010). The plot for Brazilians was
generated as described in Figure 5.
FIGURE 7 | Allele-specific F ST values for 38 PGx polymorphisms in
HapMap CEU vs.YRI and in Brazilians with >90% European ancestry
vs. Brazilians with >80% African ancestry. The lines connect the F ST
values for each polymorphism in the two data sets and the box plots at the
left and right summarize the ensemble of the data for each set.
prescription requires investigation of individual ancestry. Rather,
individual genotyping should be directed to PGx polymorphisms
of proven clinical utility for the specific medical condition being
treated, irrespective of biogeographical ancestry.
Drug assessment and regulatory processes in Brazil are carried
out by the National Health Surveillance Agency, ANVISA, an inde-
pendently administered, financially autonomous agency, managed
by a Collegiate Board of Directors5. ANVISA has the mandate to
grant, and withdraw, product registration permits within its areas
of activity, which comprise medicines for human use. Registra-
tion of new medicines do not require, that clinical trials be carried
out in the Brazilian population, and evaluation of the medicine’s
efficacy and toxicity is based mainly, if not exclusively, on foreign
data. Despite the increasing enrolment of non–Caucasian sub-
jects in global drug development programs, most data submitted
to ANVISA derive from white Europeans and North Americans.
We have recently shown that there is little pharmacogenetic diver-
gence between the HapMap CEU cohort of European extraction
and White Brazilians, such that only CYP3A5∗3 among 44 poly-
morphisms exceeded the F ST threshold for moderate divergence.
By contrast, F ST analyses revealed very large divergence between
CEU and Black Brazilians for CYP3A5∗3 and moderate divergence
for eight other polymorphisms, including another CYP3A5 SNP
(CYP3A5∗6) and SNPs in the ABCB1, SLCO1B3, and SLCO1B1
genes. These findings represent a caveat against extrapolation of
PGx data from European-derived (“Caucasian”) cohorts to the
ensemble of Brazilians.
Admixture is common in all developing nations in the Amer-
ican continent, although the relative contributions of the three
major ancestral roots – native American, European, and sub-
Saharan African – vary among these nations, as well as among
ethnic groups and geographical regions within a given coun-
try. Hence, extrapolation of conclusions drawn from PGx stud-
ies in Brazilians to other admixed Latin American populations
5http://www.anvisa.gov.br/eng/index.htm
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must take into account the specific patterns of population struc-
ture and diversity across the Americas. Therapeutic drugs are
usually developed and investigated for their safety and efficacy
in geographical and ethnical populations that do not encom-
pass the diversity of Latin American peoples. Drivers and bar-
riers to the adoption of PGx in developing countries, and spe-
cific ways in which these countries could benefit from PGx-
based drug therapy deserve greater attention from academic
and industrial scientists, prescribers, and legislators in develop-
ing nations across the Americas. This goal is not likely to be
achieved simply by mandates to include subjects from ethnic
minorities in clinical drug trials, especially when these groups
are labeled by phenotypes which do not accurately reflect genetic
ancestry (Suarez-Kurtz, 2005, 2010; Suarez-Kurtz and Pena, 2006,
2007).
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